Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

NCT ID: NCT01329029

Last Updated: 2016-12-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 1945 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-05-31
• Study Completion Date: 2014-05-31

Brief Summary

The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects.

Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.

Detailed Description

The drug tested in this study is called Roflumilast. Roflumilast is being developed to treat people who have chronic obstructive pulmonary disease (COPD). This study investigated the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate, pulmonary function, and major adverse cardiovascular events (MACE) in COPD patients who were concomitantly treated with a fixed combination of long-acting beta-agonists (LABA) and inhaled glucocorticosteroids.

The study was targeted to enroll approximately 1934 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

• Roflumilast 500 μg once daily
• Placebo (dummy inactive pill) - this was a tablet that looked like the study drug but had no active ingredient

Trial treatment was taken in the morning by mouth after breakfast with some water.

The trial consisted of the following periods:

• Single-blind baseline period (4 weeks) during which all patients received placebo.
• Double-blind treatment period (52 weeks) during which patients received either roflumilast or matching placebo.
• Safety follow-up (30 days after end of treatment (Vend) or premature discontinuation date) in case of ongoing Adverse Events at Vend, if necessary.
• Follow-up visit 12 weeks after end of treatment, at Week 64 (VFU), only for patients who completed the trial as scheduled.

This multi-center trial was conducted worldwide. The overall time to participate in this study was up to 64 weeks. Participants made multiple visits to the clinic which included a follow-up visit at week 64.

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD; Roflumilast; Daxas

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Roflumilast

concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid

Group Type: ACTIVE_COMPARATOR

Roflumilast

Intervention Type: DRUG

500 µg, once daily

Placebo

concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

once daily

Interventions

Roflumilast

500 µg, once daily

Intervention Type: DRUG

Placebo

once daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Giving written informed consent
• History of COPD (according to GOLD 2009) for at least 12 months prior to baseline Visit V0 associated with chronic productive cough for 3 months in each of the 2 years prior to baseline visit (with other causes of productive cough excluded)
• Age ≥ 40 years
• Forced expiratory volume after one second (FEV1)/forced vital capacity (FVC) ratio (post-bronchodilator) < 70%
• FEV1 (post-bronchodilator) ≤ 50% of predicted
• At least two documented moderate or severe COPD exacerbations within one year prior to baseline visit
• Patients must be pre-treated with LABA and ICS for at least 12 months before baseline Visit V0. Up to 3 months before baseline Visit V0 free or fixed combinations of LABA and ICS are allowed, including changes in dose, active substances, and brands. In the last 3 months before baseline Visit V0 patients must be pre-treated with fixed combinations of LABA and ICS at a constant dose (maximum approved dosage strength of the combination).
• Former smoker (defined as smoking cessation at least one year ago) or current smoker both with a smoking history of at least 20 pack years

Exclusion Criteria

• Exacerbations not resolved at first baseline visit
• Diagnosis of asthma and/or other relevant lung disease
• Known alpha-1-antitrypsin deficiency

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

AstraZeneca AstraZeneca

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Nycomed Investigational Site

Box Hill, , Australia

Nycomed Investigational Site

Clayton, , Australia

Nycomed Investigational Site

Concord, , Australia

Nycomed Investigational site

Daws Park, , Australia

Nycomed Investigational Site

Frankston, , Australia

Nycomed Investigational Site

Heidelberg, , Australia

Nycomed Investigational Site

Parkville, , Australia

Nycomed Investigational Site

Toorak Gardens, , Australia

Nycomed Investigational Site

Feldbach, , Austria

Nycomed Investigational Site

Graz, , Austria

Nycomed Investigational Site

Salzburg, , Austria

Nycomed Investigational Site

Vienna, , Austria

Nycomed Investigational Site

Brussels, , Belgium

Nycomed Investigational Site

Brussels, , Belgium

Nycomed Investigational Site

Halen, , Belgium

Nycomed Investigational Site

Liège, , Belgium

Nycomed Investigational Site

Malmedy, , Belgium

Nycomed Investigational Site

Belo Horizonte, , Brazil

Nycomed Investigational Site

Botucatu, , Brazil

Nycomed Investigational Site

Florianópolis, , Brazil

Nycomed Investigational Site

Goiânia, , Brazil

Nycomed Investigational Site

Porto Alegre, , Brazil

Nycomed Investigational Site

Rio de Janeiro, , Brazil

Nycomed Investigational Site

São Paulo, , Brazil

Nycomed Investigational Site

Vitória, , Brazil

Nycomed Investigational Site

Hamilton, , Canada

Nycomed Investigational Site

Kingston, , Canada

Nycomed Investigational Site

Lachine, , Canada

Nycomed Investigational Site

Niagara Falls, , Canada

Nycomed Investigational Site

Richmond Hill, , Canada

Nycomed Investigational Site

Toronto, , Canada

Nycomed Investigational Site

Toronto, , Canada

Nycomed Investigational Site

Winnepeg, , Canada

Nycomed Investigational Site

Hellerup, , Denmark

Nycomed Investigational Site

Hillerød, , Denmark

Nycomed Investigational Site

Hvidovre, , Denmark

Nycomed Investigational Site

København NV, , Denmark

Nycomed Investigational Site

Férolles-Attilly, , France

Nycomed Investigational Site

Nîmes, , France

Nycomed Investigational Site

Poitiers, , France

Nycomed Investigational Site

Saint-Laurent-du-Var, , France

Nycomed Investigational Site

Strasbourg, , France

Nycomed Investigational Site

Berlin, , Germany

Nycomed Investigational Site

Berlin, , Germany

Nycomed Investigational Site

Berlin, , Germany

Nycomed Investigational Site

Fürth, , Germany

Nycomed Investigational Site

Großhansdorf, , Germany

Nycomed Investigational Site

Hanover, , Germany

Nycomed Investigational Site

Homburg, , Germany

Nycomed Investigational Site

Koblenz, , Germany

Nycomed Investigational Site

Marburg, , Germany

Nycomed Investigational Site

Rüdersdorf, , Germany

Nycomed Investigational Site

Alexandroupoli, , Greece

Nycomed Investigational Site

Athens, , Greece

Nycomed Investigational Site

Athens, , Greece

Nycomed Investigational Site

Heraklion, Crete, , Greece

Nycomed Investigational Site

Kavala, , Greece

Nycomed Investigational Site

Larissa, , Greece

Nycomed Investigational Site

Marousi, , Greece

Nycomed Investigational Site

Thessaloniki, , Greece

Nycomed Investigational Site

Balassagyarmat, , Hungary

Nycomed Investigational Site

Budapest, , Hungary

Nycomed Investigational Site

Cegléd, , Hungary

Nycomed Investigational Site

Csorna, , Hungary

Nycomed Investigational Site

Deszk, , Hungary

Nycomed Investigational Site

Érd, , Hungary

Nycomed Investigational Site

Miskolc, , Hungary

Nycomed Investigational Site

Nyíregyháza, , Hungary

Nycomed Investigational Site

Pécs, , Hungary

Nycomed Investigational Site

Siófok, , Hungary

Nycomed Investigational Site

Sopron, , Hungary

Nycomed Investigational Site

Szombathely, , Hungary

Nycomed Investigational Site

Törökbálint, , Hungary

Nycomed Investigational Site

Ashkelon, , Israel

Nycomed Investigational Site

Beersheba, , Israel

Nycomed Investigational Site

Haifa, , Israel

Nycomed Investigational Site

Haifa, , Israel

Nycomed Investigational Site

Holon, , Israel

Nycomed Investigational Site

Jerusalem, , Israel

Nycomed Investigational Site

Jerusalm, , Israel

Nycomed Investigational Site

Kfar Saba, , Israel

Nycomed Investigational Site

Petah Tikva, , Israel

Nycomed Investigational Site

Rehovot, , Israel

Nycomed Investigational Site

Tel Aviv, , Israel

Nycomed Investigational Site

Tel Aviv, , Israel

Nycomed Investigational Site

Tel Litwinsky, , Israel

Nycomed Investigational Site

Ferrara, , Italy

Nycomed Investigational Site

Genova, , Italy

Nycomed Investigational Site

Milan, , Italy

Nycomed Investigational Site

Milan, , Italy

Nycomed Investigational Site

Modena, , Italy

Nycomed Investigational Site

Monza, , Italy

Nycomed Investigational Site

Pordenone, , Italy

Nycomed Investigational Site

Roma, , Italy

Nycomed Investigational Site

's-Hertogenbosch, , Netherlands

Nycomed Investigational Site

Amersfoort, , Netherlands

Nycomed Investigational Site

Arnhem, , Netherlands

Nycomed Investigational Site

Enschede, , Netherlands

Nycomed Investigational Site

Heerlen, , Netherlands

Nycomed Investigational Site

Hoorn, , Netherlands

Nycomed Investigational Site

Bialystok, , Poland

Nycomed Investigational Site

Bydgoszcz, , Poland

Nycomed Investigational Site

Gliwice, , Poland

Nycomed Investigational Site

Katowice, , Poland

Nycomed Investigational Site

Lodz, , Poland

Nycomed Investigational Site

Lodz, , Poland

Nycomed Investigational Site

Lodz, , Poland

Nycomed Investigational Site

Lublin, , Poland

Nycomed Investigational Site

Oleśnica, , Poland

Nycomed Investigational Site

Ostrów Wielkopolski, , Poland

Nycomed Investigational Site

Tarnów, , Poland

Nycomed Investigational Site

Warsaw, , Poland

Nycomed Investigational Site

Wroclaw, , Poland

Nycomed Investigational Site

Wroclaw, , Poland

Nycomed Investigational Site

Zawadzkie, , Poland

Nycomed Investigational Site

Chelyabinsk, , Russia

Nycomed Investigational Site

Kazan', , Russia

Nycomed Investigational Site

Kemerovo, , Russia

Nycomed Investigational Site

Moscow, , Russia

Nycomed Investigational Site

Moscow, , Russia

Nycomed Investigational Site

Moscow, , Russia

Nycomed Investigational Site

Moscow, , Russia

Nycomed Investigational Site

Nizhny Novgorod, , Russia

Nycomed Investigational Site

Novosibirsk, , Russia

Nycomed Investigational Site

Novosibirsk, , Russia

Nycomed Investigational Site

Saint Petersburg, , Russia

Nycomed Investigational Site

Saint Petersburg, , Russia

Nycomed Investigational Site

Saint Petersburg, , Russia

Nycomed Investigational Site

Samara, , Russia

Nycomed Investigational Site

Saratov, , Russia

Nycomed Investigational Site

Smolensk, , Russia

Nycomed Investigational Site

Volgograd, , Russia

Nycomed Investigational Site

Vsevolozhsk, , Russia

Nycomed Investigational Site

Yaroslavl, , Russia

Nycomed Investigational Site

Banská Bystrica, , Slovakia

Nycomed Investigational Site

Bardejov, , Slovakia

Nycomed Investigational Site

Bratislava, , Slovakia

Nycomed Investigational Site

Bratislava, , Slovakia

Nycomed Investigational Site

Košice, , Slovakia

Nycomed Investigational Site

Martin, , Slovakia

Nycomed Investigational Site

Nitra, , Slovakia

Nycomed Investigational Site

Nové Zámky, , Slovakia

Nycomed Investigational Site

Spišská Nová Ves, , Slovakia

Nycomed Investigational Site

Auckland Park, Johannesburg Gauteng, , South Africa

Nycomed Investigational Site

Benoni Gauteng, , South Africa

Nycomed Investigational Site

Bloemfontein Free State, , South Africa

Nycomed Investigational Site

Cape Town Western Cape, , South Africa

Nycomed Investigational Site

Durban Kwazulu-Natal, , South Africa

Nycomed Investigational Site

Johannesburg, , South Africa

Nycomed Investigational Site

Morningside, Johannesburg Gauteng, , South Africa

Nycomed Investigational Site

Thabazimbi Limpopo, , South Africa

Nycomed Investigational Site

Umkomaas Kwazulu-Natal, , South Africa

Nycomed Investigational Site

Witbank Mpumalanga, , South Africa

Nycomed Investigational Site

Anyang, , South Korea

Nycomed Investigational Site

Cheongju-si, , South Korea

Nycomed Investigational Site

Daegu, , South Korea

Nycomed Investigational Site

Seoul, , South Korea

Nycomed Investigational Site

Seoul, , South Korea

Nycomed Investigational Site

Seoul, , South Korea

Nycomed Investigational Site

Wŏnju, , South Korea

Nycomed Investigational Site

Barcelona, , Spain

Nycomed Investigational Site

Guadalajara, , Spain

Nycomed Investigational Site

Madrid, , Spain

Nycomed Investigational Site

Pozuelo de Alarcón, , Spain

Nycomed Investigational Site

Santander, , Spain

Nycomed Investigational Site

Terrassa, , Spain

Nycomed Investigational Site

Valencia, , Spain

Nycomed Investigational Site

Ankara, , Turkey (Türkiye)

Nycomed Investigational Site

Çanakkale, , Turkey (Türkiye)

Nycomed Investigational Site

Istanbul, , Turkey (Türkiye)

Nycomed Investigational Site

Izmir, , Turkey (Türkiye)

Nycomed Investigational Site

Kocaeli, , Turkey (Türkiye)

Nycomed Investigational Site

Konya, , Turkey (Türkiye)

Nycomed Investigational Site

Mersin, , Turkey (Türkiye)

Nycomed Investigational Site

Edinburgh, , United Kingdom

Nycomed Investigational Site

Glasgow, , United Kingdom

Nycomed Investigational Site

Liverpool, , United Kingdom

Nycomed Investigational Site

London, , United Kingdom

Nycomed Investigational Site

London, , United Kingdom

Nycomed Investigational Site

Norwich, , United Kingdom

Countries

Australia; Austria; Belgium; Brazil; Canada; Denmark; France; Germany; Greece; Hungary; Israel; Italy; Netherlands; Poland; Russia; Slovakia; South Africa; South Korea; Spain; Turkey (Türkiye); United Kingdom

References

Facius A, Marostica E, Gardiner P, Watz H, Lahu G. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease. Clin Pharmacokinet. 2018 Aug;57(8):1029-1038. doi: 10.1007/s40262-018-0671-4.

Reference Type: DERIVED

PMID: 29797235 (View on PubMed)

Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Roman J, Purkayastha D, Bagul N, Rennard SI. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. Am J Respir Crit Care Med. 2018 Nov 15;198(10):1268-1278. doi: 10.1164/rccm.201712-2493OC.

Reference Type: DERIVED

PMID: 29763572 (View on PubMed)

Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017 Jul 5;50(1):1700158. doi: 10.1183/13993003.00158-2017. Print 2017 Jul. No abstract available.

Reference Type: DERIVED

PMID: 28679611 (View on PubMed)

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13.

Reference Type: DERIVED

PMID: 25684586 (View on PubMed)

Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis. 2012;7:375-82. doi: 10.2147/COPD.S31100. Epub 2012 Jun 20.

Reference Type: DERIVED

PMID: 22791991 (View on PubMed)

Other Identifiers

2010-019685-87

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1141-7422

Identifier Type: REGISTRY

Identifier Source: secondary_id

RO-2455-404-RD

Identifier Type: -

Identifier Source: org_study_id